ARWR · Arrowhead Pharmaceuticals, Inc. · Executive Compensation
$61.54
-0.81 (-1.30%)
At close · Oct 6
Return incl. dividend (before tax)
Market Cap
$9.36B
Shares
141.25M
Volume · Oct 6
1.68M
Avg daily vol (3M)
1.9M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Christopher Anzalone | President and Chief Executive Officer | $12,423,473 |
| Patrick O’Brien | Chief Operating Officer and General Counsel | $3,933,570 |
| Kenneth A. Myszkowski | Chief Financial Officer | $3,512,376 |
| James Hamilton | Chief of Discovery and Translational Medicine | $3,487,444 |
| Javier San Martin | Former Chief Medical Officer | $3,456,564 |
| Tracie Oliver | Former Chief Commercial Officer | $3,076,780 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Christopher Anzalone | President and Chief Executive Officer | $9,918,093 |
| Patrick O’Brien | Chief Operating Officer and General Counsel | $3,310,337 |
| Kenneth A. Myszkowski | Chief Financial Officer | $3,119,143 |
| Javier San Martin | Former Chief Medical Officer | $3,095,982 |
| James Hamilton | Chief of Discovery and Translational Medicine | $3,046,943 |
| Tracie Oliver | Former Chief Commercial Officer | $873,822 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Christopher Anzalone | President and Chief Executive Officer | $12,031,969 |
| Kenneth A. Myszkowski | Chief Financial Officer | $4,739,552 |
| Patrick O’Brien | Chief Operating Officer and General Counsel | $4,727,863 |
| James Hamilton | Chief of Discovery and Translational Medicine | $4,323,314 |
| Tracie Oliver | Former Chief Commercial Officer | $2,744,471 |
| Javier San Martin | Former Chief Medical Officer | $704,744 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Christopher Anzalone | President and Chief Executive Officer | $24,703,855 |
| Patrick O’Brien | Chief Operating Officer and General Counsel | $5,336,926 |
| Kenneth A. Myszkowski | Chief Financial Officer | $5,333,570 |
| James Hamilton | Chief of Discovery and Translational Medicine | $4,509,947 |
| Javier San Martin | Chief Medical Officer | $644,746 |
| Tracie Oliver | Chief Commercial Officer | — |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Bruce Given | COO | $16,343,808 |
| Bruce Given, M.D. | Former Chief Operating Officer | $16,343,808 |
| Christopher Anzalone | President and Chief Executive Officer | $14,294,517 |
| James Hassard | Chief Commercial Officer | $7,918,296 |
| Javier San Martin | Chief Medical Officer | $7,899,071 |
| Curt Bradshaw | Former Chief Scientific Officer | $6,373,206 |
| Kenneth A. Myszkowski | Chief Financial Officer | $6,081,852 |
| Patrick O’Brien | Chief Operating Officer and General Counsel | $5,123,502 |
| James Hamilton | Chief of Discovery and Translational Medicine | $3,412,877 |
| Tracie Oliver | Chief Commercial Officer | — |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Bruce Given, M.D. | Former Chief Operating Officer | $3,958,759 |
| Bruce Given | COO | $3,958,759 |
| James Hassard | Chief Commercial Officer | — |
| Javier San Martin | Chief Medical Officer | — |
| Curt Bradshaw | Former Chief Scientific Officer | — |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Bruce Given, M.D. | Former Chief Operating Officer | $1,552,061 |
| Bruce Given | COO | $1,552,061 |
| James Hassard | Chief Commercial Officer | — |
| Curt Bradshaw | Former Chief Scientific Officer | — |
| Javier San Martin | Chief Medical Officer | — |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Dr. Matt Cohen, M.D., M.B.A. | director | Appointed | 2026-06-16 |
| Daniel Apel | Chief Financial Officer | Appointed | 2025-04-15 |
| Ken Myszkowski | Chief Financial Officer | Retired | 2025-04-15 |
| Douglas Ingram | director | Appointed | 2025-02-07 |
| Douglass Given, M.D., Ph.D. | Chairman of the Board | Retired | 2024-12-18 |
| Hongbo Lu, Ph.D. | independent director | Appointed | 2024-02-22 |
| Marianne De Backer | director | Resigned | 2023-02-14 |
| Patrick O'Brien | Chief Operating Officer and General Counsel | Appointed | 2022-07-20 |
Key facts
CIK
879407
CUSIP
04280A100
13F (30d)
10 filings
10 filers
Visit website
Investor relations